晚期肝癌药物治疗进展  

Progress in the drug treatment of advanced hepatocellular carcinoma

作　　者：田雨萌 韩涛[1] 赵明芳[1] Tian Yumeng;Han Tao;Zhao Mingfang(Second Ward of Oncology Department,the First Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院肿瘤内科二病房,辽宁沈阳110001

出　　处：《实用药物与临床》2023年第1期72-78,共7页Practical Pharmacy and Clinical Remedies

摘　　要：原发性肝细胞肝癌(HCC)是全球发病率第6位的恶性肿瘤,且确诊时常常已是晚期,伴肝内或肝外转移,无法手术根治。晚期肝癌对放化疗不敏感,严重危害患者生存与健康。目前晚期肝癌主要依靠全身治疗,包括靶向治疗、化学治疗和免疫治疗。近年来,免疫检查点抑制剂的发展,为晚期肝癌患者的治疗带来新的期望。本文系统梳理晚期肝癌诊疗现况,对晚期肝癌的最新治疗进展进行综述。The incidence rate of primary hepatocellular cancer(HCC)ranks the sixth of the world′s malignant tumors.It is often in advanced stage when being diagnosed,with intrahepatic or extrahepatic metastasis,and cannot be cured by surgery.Advanced HCC has endangered the survival and health of patients due to its insensitivity to radiotherapy and chemotherapy.Nowadays,systemic therapy is still the main treatment for HCC,including targeted therapy,chemotherapy and immunotherapy.In recent years,the development of immune checkpoint inhibitors has brought new hope to advanced HCC patients.This article sorts out current status of the diagnosis and treatment of advanced HCC systematically,and reviews the latest treatment progress of advanced HCC.

关 键 词：原发性肝癌 化学治疗 靶向治疗 免疫治疗 联合治疗 

分 类 号：R735.7[医药卫生—肿瘤]